Elad Sharon, Clinical and Translational Director, Immunotherapy Toxicity Program at Dana-Farber Cancer Institute and Co-Chair, Alliance Immuno-Oncology Committee at Alliance for Clinical Trials in Oncology, shared Vivek Subbiah’s, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, post on X, adding:
“Drug development maxim in action: When an oncology drug finds a use for a benign condition, it will work better than it did in cancer. (examples: CD19 CAR or Rituxan for many autoimmune conditions; VEGF in some neovascular eye conditions, and IGF-1R for Thyroid Eye Disease).”
Quoting Vivek Subbiah‘s post:
“Lumvoa (veligrotug-vvze) a full antagonist of IGF-1R was FDA approved for the Treatment of Thyroid Eye Disease.
We had 15 + IGF1R agents in oncology drug development – none of them made it to finish line. Genuinely great to see the mechanism finally deliver for patients, even if in a different specialty.”
Other articles featuring Elad Sharon and Vivek Subbiah on OncoDaily.